H Hirte1, E B Kennedy2, L Elit1, M Fung Kee Fung3. 1. Juravinski Cancer Centre, Hamilton, ON; 2. Program in Evidence-Based Care, Cancer Care Ontario, McMaster University, Hamilton, ON; 3. Ottawa General Hospital, Ottawa, ON.
Abstract
BACKGROUND: Systemic therapy options are needed for women with recurrent, metastatic, or persistent cervical cancer. This systematic review and clinical practice guideline were developed to address that need, and to update a 2007 guideline from Cancer Care Ontario's Program in Evidence-Based Care. METHODS: The literature between 2006 and April 2014 in the medline and embase databases, the Cochrane Database of Systematic Reviews (Issue 4, 2014), the Cochrane Central Register of Controlled Trials (Issue 3, 2014), relevant guideline databases, and conference proceedings of the American Society of Clinical Oncology (2007-2013) was searched. A working group developed draft guidelines and incorporated comments and feedback from internal and external reviewers. RESULTS: Four phase iii randomized controlled trials met the inclusion criteria for the review and provided the basis for draft recommendations. Feedback was obtained from Ontario practitioners and others abroad, which led to modifications to the draft recommendations. Three key recommendations were developed. CONCLUSIONS: The working group concluded that all patients should be offered the opportunity to participate in appropriate randomized clinical trials. Cisplatin-paclitaxel, cisplatin-vinorelbine, cisplatin-gemcitabine, and cisplatin-topotecan are recommended combinations for this patient population. The substitution of carboplatin for cisplatin in the foregoing combinations can also be recommended because carboplatin is associated with fewer adverse effects and greater ease of administration. Selection of combination chemotherapy will depend on the toxicity profile, patient preference, and other factors. Finally, bevacizumab in combination with cisplatin-paclitaxel or carboplatin-paclitaxel is recommended for a specific subset of the target population as outlined in Gynecologic Oncology Group study 0240.
BACKGROUND: Systemic therapy options are needed for women with recurrent, metastatic, or persistent cervical cancer. This systematic review and clinical practice guideline were developed to address that need, and to update a 2007 guideline from Cancer Care Ontario's Program in Evidence-Based Care. METHODS: The literature between 2006 and April 2014 in the medline and embase databases, the Cochrane Database of Systematic Reviews (Issue 4, 2014), the Cochrane Central Register of Controlled Trials (Issue 3, 2014), relevant guideline databases, and conference proceedings of the American Society of Clinical Oncology (2007-2013) was searched. A working group developed draft guidelines and incorporated comments and feedback from internal and external reviewers. RESULTS: Four phase iii randomized controlled trials met the inclusion criteria for the review and provided the basis for draft recommendations. Feedback was obtained from Ontario practitioners and others abroad, which led to modifications to the draft recommendations. Three key recommendations were developed. CONCLUSIONS: The working group concluded that all patients should be offered the opportunity to participate in appropriate randomized clinical trials. Cisplatin-paclitaxel, cisplatin-vinorelbine, cisplatin-gemcitabine, and cisplatin-topotecan are recommended combinations for this patient population. The substitution of carboplatin for cisplatin in the foregoing combinations can also be recommended because carboplatin is associated with fewer adverse effects and greater ease of administration. Selection of combination chemotherapy will depend on the toxicity profile, patient preference, and other factors. Finally, bevacizumab in combination with cisplatin-paclitaxel or carboplatin-paclitaxel is recommended for a specific subset of the target population as outlined in Gynecologic Oncology Group study 0240.
Entities:
Keywords:
Cervical cancer; chemotherapy; practice guideline; systematic review; systemic therapy
Authors: Harry J Long; Robert A Nelimark; Karl C Podratz; Vera Suman; Gary L Keeney; Daniel A Nikcevich; John W Kugler; Kendrith M Rowland; Carl G Kardinal; Edward J Wos Journal: Gynecol Oncol Date: 2005-09-26 Impact factor: 5.482
Authors: G P Browman; M N Levine; E A Mohide; R S Hayward; K I Pritchard; A Gafni; A Laupacis Journal: J Clin Oncol Date: 1995-02 Impact factor: 44.544
Authors: Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson Journal: N Engl J Med Date: 2006-12-14 Impact factor: 91.245
Authors: Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Don S Dizon; Helen J Mackay; Gillian M Thomas; Theresa L Werner; Elise C Kohn; Dina Hess; Peter G Rose; Allan L Covens Journal: Cancer Date: 2014-04-15 Impact factor: 6.860
Authors: Bradley J Monk; Michael W Sill; D Scott McMeekin; David E Cohn; Lois M Ramondetta; Cecelia H Boardman; Jo Benda; David Cella Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Krishnansu S Tewari; Michael W Sill; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Philip J DiSaia; Larry J Copeland; William T Creasman; Frederick B Stehman; Mark F Brady; Robert A Burger; J Tate Thigpen; Michael J Birrer; Steven E Waggoner; David H Moore; Katherine Y Look; Wui-Jin Koh; Bradley J Monk Journal: Lancet Date: 2017-07-27 Impact factor: 79.321
Authors: Jennifer R Diamond; Barbara Goff; Martin D Forster; Johanna C Bendell; Carolyn D Britten; Michael S Gordon; Hani Gabra; David M Waterhouse; Mark Poole; D Ross Camidge; Erika Hamilton; Kathleen M Moore Journal: Invest New Drugs Date: 2017-03-10 Impact factor: 3.850
Authors: Linus T Chuang; Sarah Temin; Rolando Camacho; Alfonso Dueñas-Gonzalez; Sarah Feldman; Murat Gultekin; Vandana Gupta; Susan Horton; Graciela Jacob; Elizabeth A Kidd; Kennedy Lishimpi; Carolyn Nakisige; Joo-Hyun Nam; Hextan Yuen Sheung Ngan; William Small; Gillian Thomas; Jonathan S Berek Journal: J Glob Oncol Date: 2016-05-25
Authors: Carly A Burmeister; Saif F Khan; Georgia Schäfer; Nomonde Mbatani; Tracey Adams; Jennifer Moodley; Sharon Prince Journal: Tumour Virus Res Date: 2022-04-20
Authors: Barbara A Conley; Lou Staudt; Naoko Takebe; David A Wheeler; Linghua Wang; Maria F Cardenas; Viktoriya Korchina; Jean Claude Zenklusen; Lisa M McShane; James V Tricoli; Paul M Williams; Irina Lubensky; Geraldine O'Sullivan-Coyne; Elise Kohn; Richard F Little; Jeffrey White; Shakun Malik; Lyndsay N Harris; Bhupinder Mann; Carol Weil; Roy Tarnuzzer; Chris Karlovich; Brian Rodgers; Lalitha Shankar; Paula M Jacobs; Tracy Nolan; Sean M Berryman; Julie Gastier-Foster; Jay Bowen; Kristen Leraas; Hui Shen; Peter W Laird; Manel Esteller; Vincent Miller; Adrienne Johnson; Elijah F Edmondson; Thomas J Giordano; Benjamin Kim; S Percy Ivy Journal: J Natl Cancer Inst Date: 2021-01-04 Impact factor: 11.816